使用深度学习量化早产儿视网膜病变 severity 评分以监测治疗后疾病消退
这项回顾性队列研究基于早产儿视网膜病变影像与信息学联盟9个三级转诊中心的数据,纳入46只发生需治疗型早产儿视网膜病变(TR-ROP)且具备治疗前后影像的眼睛。深度学习算法给出的血管严重度评分在治疗前2周升高、治疗时达峰值、治疗后至少2周下降,初始治疗时评分较高的眼睛后续需要激光再治疗。
要点
- TR-ROP眼平均血管严重度评分治疗前2周为4.19,治疗时达峰值7.43,治疗后至少2周降至4.00(均P < .001)。
- 初始治疗时血管严重度评分较高的眼睛后续需要激光再治疗,与单次治疗眼相比差异有统计学意义(P < .001)。
- 该评分似可一致反映TR-ROP眼的临床疾病进展与治疗后消退。
核心结论
- 该定量ROP血管严重度评分似可一致反映TR-ROP眼的临床疾病进展和治疗后消退。
- 研究结果可能对监测ROP患者的治疗失败和疾病复发、以及确定侵袭性疾病眼初次治疗的合适疾病严重程度水平有启示。
研究设计与样本
- 回顾性队列研究,使用早产儿视网膜病变影像与信息学联盟数据,该联盟包括北美9个三级转诊中心,对高危婴儿进行大规模ROP筛查。
- 评估2011年7月至2016年12月间871名婴儿的5255次临床眼科检查图像。
- 纳入符合ROP筛查标准、发生TR-ROP、且在治疗前4周内、治疗后4周内及治疗时均有图像捕捉的早产儿。
- 5255只受检眼中91只发生TR-ROP,其中46只眼基于可用图像符合纳入标准。
- 46只眼患者的平均(SD)出生体重为653(185)g,平均(SD)孕周为24.9(1.3)周。
主要发现
- 平均(SD)ROP血管严重度评分在治疗前2周显著升高至4.19(1.75),治疗时达峰值7.43(1.89),治疗后至少2周下降至4.00(1.88)(均P < .001)。
- 需要激光再治疗的眼睛在初始治疗时ROP血管严重度评分高于接受单次治疗的眼睛(P < .001)。
关键数值与推荐
- 深度学习分类器在每次检查时给出连续ROP血管严重度评分,范围从1(正常)到9(最严重)。
- 主要结局为治疗前、治疗时和治疗后的平均(SD)ROP血管严重度评分。
- 次要结局为激光治疗眼与血管内皮生长因子拮抗剂贝伐珠单抗治疗眼之间ROP血管严重度评分的差异。
- 组间差异使用非配对双尾t检验并经Bonferroni校正评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide, but treatment failure and disease recurrence are important causes of adverse outcomes in patients with treatment-requiring ROP (TR-ROP). OBJECTIVES: To apply an automated ROP vascular severity score obtained using a deep learning algorithm and to assess its utility for objectively monitoring ROP regression after treatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Imaging and Informatics in ROP consortium, which comprises 9 tertiary referral centers in North America that screen high volumes of at-risk infants for ROP. Images of 5255 clinical eye examinations from 871 infants performed between July 2011 and December 2016 were assessed for eligibility in the present study. The disease course was assessed with time across the numerous examinations for patients with TR-ROP. Infants born prematurely meeting screening criteria for ROP who developed TR-ROP and who had images captured within 4 weeks before and after treatment as well as at the time of treatment were included. MAIN OUTCOMES AND MEASURES: The primary outcome was mean (SD) ROP vascular severity score before, at time of, and after treatment. A deep learning classifier was used to assign a continuous ROP vascular severity score, which ranged from 1 (normal) to 9 (most severe), at each examination. A secondary outcome was the difference in ROP vascular severity score among eyes treated with laser or the vascular endothelial growth factor antagonist bevacizumab. Differences between groups for both outcomes were assessed using unpaired 2-tailed t tests with Bonferroni correction. RESULTS: Of 5255 examined eyes, 91 developed TR-ROP, of which 46 eyes met the inclusion criteria based on the available images. The mean (SD) birth weight of those patients was 653 (185) g, with a mean (SD) gestational age of 24.9 (1.3) weeks. The mean (SD) ROP vascular severity scores significantly increased 2 weeks prior to treatment (4.19 [1.75]), peaked at treatment (7.43 [1.89]), and decreased for at least 2 weeks after treatment (4.00 [1.88]) (all P < .001). Eyes requiring retreatment with laser had higher ROP vascular severity scores at the time of initial treatment compared with eyes receiving a single treatment (P < .001). CONCLUSIONS AND RELEVANCE: This quantitative ROP vascular severity score appears to consistently reflect clinical disease progression and posttreatment regression in eyes with TR-ROP. These study results may have implications for the monitoring of patients with ROP for treatment failure and disease recurrence and for determining the appropriate level of disease severity for primary treatment in eyes with aggressive disease.
引用
- Gupta K, Campbell JP, Taylor S, et al. A Quantitative Severity Scale for Retinopathy of Prematurity Using Deep Learning to Monitor Disease Regression After Treatment. JAMA Ophthalmol. 2019. PMID: 31268499. doi:10.1001/jamaophthalmol.2019.2442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。